Treatment with NPR3 inhibitor ANP (4–23) in a murine model of focal segmental glomerulosclerosis (FSGS) showed some promising results but faced with the limitation of fast degradation13. This evidence concerns the gene NPR3 and focal segmental glomerulosclerosis.